Do you have any concerns about using long-acting cabotegravir/rilpivirine in obese patients with HIV?
1 Answers
Mednet Member
Infectious Disease · University of Texas Southwestern Medical School
There have been concerns raised about adequate drug levels being maintained in patients with high BMI. One concern is that injections may be deposited in subcutaneous rather than intramuscular tissue. A recent computer modeling study also indicated subtherapeutic drug levels in patients with BMI >40...